Search Within

Pallawi Torka

Formats
  1. Meeting Abstract (43)
  2. Journal Article (14)
  3. Research Letter (3)
  4. Correspondence (2)
  5. Editorial (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Hematology-Oncology Fellows (29)
  6. Sloan Kettering Institute Postdocs (28)

More Groups

People
  1. Paul Hamlin (30)
  2. Anita Kumar (28)
  3. Paola Ghione (28)
  4. Andrew Zelenetz (27)
  5. Gilles Salles (27)
  6. Lorenzo Falchi (27)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (27)
Publications
  1. Blood (39)
  2. Blood Cancer Journal (4)
  3. Hematological Oncology (4)
  4. Blood Advances (3)
  5. Clinical Lymphoma, Myeloma and Leukemia (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. Elsevier Inc. (4)
  3. Nature Publishing Group (4)
  4. Wiley Blackwell (4)
  5. Biomed Central Ltd (3)
  6. American Society of Clinical Oncology (2)

More Publishers

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826
    Meeting Abstract

    Rutherford, S. C.; Li, H.; Herrera, A. F.; Leblanc, M.; Ahmed, S.; Davison, K. L.; Casulo, C.; Bartlett, N. L.; Tuscano, J. M.; Hess, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Allogeneic stem cell transplant and CD30 directed CART cell therapies are associated with improved survival in classical Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: Real world analysis from 14 US academic centers
    Meeting Abstract

    Voorhees, T.; Grover, N. S.; McLaughlin, E.; Florindez, J. A.; Moyo, T. K.; Reves, H.; Sumransub, N.; Deshpande, S.; Rose, A.; Duarte, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): First results of a multicenter phase 2 study
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Palomba, M. L.; Kumar, A.; Torka, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: A report from The North American Mantle Cell Lymphoma Consortium
    Journal Article

    Vose, J. M.; Fu, K.; Wang, L.; Mansoor, A.; Stewart, D.; Cheng, H.; Smith, L.; Yuan, J.; Qureishi, H. N.; Link, B. K.; more...
    Journal of Hematology & Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: A multicenter cohort study
    Correspondence

    Epperla, N.; Feng, L.; Shah, N. N.; Fitzgerald, L.; Shah, H.; Stephens, D. M.; Lee, C. J.; Ollila, T.; Shouse, G.; Danilov, A. V.; more...
    Journal of Hematology & Oncology (2023)

    Fulltext@MSK | Save
  • DLBCL in older adults
    Meeting Abstract

    Torka, P.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response
    Research Letter

    Akhtar, O. S.; Cao, B.; Wang, X.; Torka, P.; Al-Jumayli, M.; Locke, F. L.; Freeman, C. L.
    Blood Advances (2023)

    Fulltext@MSK | Save